These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26351314)

  • 1. Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
    Ishida H; Ichikawa W; Sasaki Y
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
    Srivastava N; VanderLaan PA; Kelly CP; Costa DB
    J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma.
    Sato Y; Fujimoto D; Shibata Y; Seo R; Suginoshita Y; Imai Y; Tomii K
    Jpn J Clin Oncol; 2014 Sep; 44(9):872-5. PubMed ID: 24966207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
    Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
    Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with ceritinib after crizotinib induced hepatitis.
    Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
    Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L; Zhang H; Shao W; Chen B
    Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
    Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
    Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
    Koizumi T; Fukushima T; Tatai T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S
    Lung Cancer; 2015 Apr; 88(1):112-3. PubMed ID: 25678258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer.
    Brosseau S; Gounant V; Choudat L; Pluvy J; Zalcman G; Khalil A
    Diagn Interv Imaging; 2018 Apr; 99(4):267-268. PubMed ID: 29472032
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS
    Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
    Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
    Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
    Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
    Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
    Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
    J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.
    Yoneshima Y; Okamoto I; Arimura-Omori M; Kimura S; Hidaka-Fujimoto N; Iwama E; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Apr; 33(2):510-2. PubMed ID: 25433426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
    Awad MM; Lax TP; Slawski BR; Shaw AT
    J Thorac Oncol; 2014 Nov; 9(11):1726-8. PubMed ID: 25436807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.